ArticleMetabolic brain disease2025
Human placental extract rescues hippocampal damage associated with cognitive impairment in diabetic male rats through antioxidative, anti-inflammatory, and neuromodulatory activities.
Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Retracted
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Memory and cognitive impairment have emerged as significant comorbidities associated with diabetes, yet effective treatment remains elusive. Various studies have shown that human placental extract (HPE) is rich in bioactive molecules that exhibit anti-inflammatory, antioxidant, anti-apoptotic, and immunomodulatory properties. However, the impact of HPE on memory and cognitive decline is not well understood. This study aimed to investigate the therapeutic effects of HPE on memory and cognitive dysfunction induced by streptozotocin (STZ) in rats, while also exploring the underlying mechanisms. To induce type 2 diabetes mellitus (T2DM), rats were first fed a high-fat diet for two weeks, followed by a single intraperitoneal injection of STZ (40 mg/kg body weight) and subsequently treated with HPE (20 mg/kg body weight per day) for 14 days. The results of our behavioral tests demonstrated that HPE significantly enhanced learning, memory, and cognitive function in rats subjected to STZ administration. Specifically, HPE increased the discrimination index in the novel object recognition test from a negative value in STZ rats to a positive value in treated rats and improved spontaneous alternation in the T-maze from 41.25 ± 8.25% to 74.50 ± 8.50%. Additionally, HPE notably improved serum levels of insulin, glucose, the homeostatic model assessment of insulin resistance (HOMA-IR), and lipid profiles compared to untreated diabetic rats. It also modulated oxidative stress markers, antioxidants, as well as pro-inflammatory cytokines and neurochemicals levels in hippocampal tissue, underscoring its antioxidant and anti-inflammatory properties. Notably, HPE treatment improved the neurological morphology of the hippocampus and reduced DNA damage. The percentage of tailed cells dropped from 25.67 ± 0.33 in diabetic rats to 13.67 ± 0.88 with HPE treatment. In summary, HPE exhibits neuroprotective effects and could serve as a promising therapeutic strategy for addressing neurodegenerative symptoms associated with T2DM in a rat model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.